文献速递慢性肾脏病

「另一」重大并发症:慢性肾脏病如何影响癌症风险与结局

The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

综述探讨慢性肾脏病(CKD)患者癌症发病与死亡风险升高的现象,指出风险因癌种而异,轻度CKD(eGFR 60-89 mL/min/1.73 m2)即可检出,且白蛋白尿独立于eGFR与特定癌种风险相关;文章分析患者因素、疾病因素和治疗因素等潜在机制,并讨论传统化疗及新型系统性抗癌治疗相关肾脏不良事件对CKD患者癌症结局的影响。

要点

  • 癌症是CKD患者仅次于心血管病的第二大死因。
  • 轻度CKD(eGFR 60-89 mL/min/1.73 m2)即可检出癌症风险升高,使用胱抑素C等敏感标志物更明显。
  • 白蛋白尿独立于eGFR与特定癌种发病和死亡风险增加相关。

核心结论

  • CKD与癌症发病和癌症死亡风险升高相关,但风险因癌种而异,且轻度CKD即可检出。
  • 白蛋白尿独立于eGFR与特定癌种发病和死亡风险增加相关。

研究设计与样本

  • 综述,探讨CKD患者癌症风险升高的潜在机制及抗癌治疗相关肾脏不良事件对癌症结局的影响。

主要发现

  • 癌症是CKD患者仅次于心血管病的第二大死因。
  • 癌症患者中CKD发病率高于非癌症人群。
  • 在不同人群中,CKD与癌症发病和癌症死亡风险升高相关,但风险因癌种而异。
  • 轻度CKD(eGFR 60-89 mL/min/1.73 m2)即可检出癌症风险升高,使用胱抑素C等敏感肾脏病标志物时更明显。
  • 白蛋白尿独立于eGFR与特定癌种发病和死亡风险增加相关。

关键数值与推荐

  • 轻度CKD定义为eGFR 60-89 mL/min/1.73 m2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer is the second leading cause of death in people with chronic kidney disease (CKD) after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in the non-cancer population. Across various populations, CKD is associated with an elevated risk of cancer incidence and cancer death compared with people without CKD, although the risks are cancer site-specific. Higher risk of cancer is detectable in mild CKD [estimated glomerular filtration rate (eGFR) 60-89 mL/min/1.73 m2], although this risk is more obvious if sensitive markers of kidney disease are used, such as cystatin C. Independent of eGFR, albuminuria is associated with increased risk of site-specific cancer incidence and death. Here, we explore the potential mechanisms for the increased risk of cancer observed in CKD, including patient factors (shared risks such as cardiometabolic disease, obesity, smoking, diet, lifestyle and environment), disease (genetic, inflammatory and infective) and treatment factors. In particular, we discuss the ways in which renal adverse events associated with conventional chemotherapies and newer systemic anti-cancer therapies (including targeted and immunotherapies) may contribute to worse cancer outcomes in people with CKD. Finally, we review the potential benefits of acknowledging increased risk of cancer in risk prediction tools used for the management of CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Lees JS, Elyan BMP, Herrmann SM, et al. The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes. Nephrol Dial Transplant. 2023. PMID: 35090037. doi:10.1093/ndt/gfac011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。